A Complex Challenge, A Novel Solution
Vaccines provide unique benefits for human health, but their broad use often is limited by two central technological challenges:
1. Maintaining thermostability during transport and storage
2. The need to administer multiple doses to provide a robust immune response against infection or disease
VitriVax has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines. ALTA can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses + additional booster doses in a single-shot administration. These technologies may also facilitate co-formulation of multiple otherwise incompatible antigens in a single injection.
ALTA Technology Platform
Thermostability + Single-Shot Administration
Thermostability: We use a spray drying process to embed antigens and adjuvants in a sugar glass matrix, protecting them against thermal and chemical degradation at temperatures as high as 70° Celsius (158° Fahrenheit) for months, eliminating the need for cold storage and complex distribution.
Single-Shot Administration: We utilize Atomic Layer Deposition (ALD) to apply nanometer-thick, precision coatings of protective metal oxides on the surface of antigen and adjuvant-containing spray dried microparticles, providing timed release of doses up to 6 months after injection.
ALTA uses highly scalable, commercially available equipment and ingredients that are already common in pharmaceuticals and generally recognized as safe (GRAS).
ALTA-enabled vaccines are engineered for extended shelf life allowing them to be easily transported anywhere in the world, stockpiled or distributed preventatively as part of emergency or military supplies. Creating a single-shot vaccine greatly increases adherence, with larger numbers of people being vaccinated and fully protected. The combination of reduced cold chain requirements during storage and transportation with single-shot administration enables vaccines to more easily reach underserved populations and geographies, helping to prevent disease and save lives.